Now showing items 1-20 of 107

    • Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. 

      Juan, O; Popat, S (2017-11)
      The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined ...
    • Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. 

      Dolly, SO; Collins, DC; Sundar, R; Popat, S; Yap, TA (2017-05)
      Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality. The traditional 'one-size-fits-all' treatment approach has now evolved into one that ...
    • Asparagine bioavailability governs metastasis in a model of breast cancer. 

      Knott, SRV; Wagenblast, E; Khan, S; Kim, SY; Soto, M; Wagner, M; Turgeon, M-O; Fish, L; Erard, N; Gable, AL; Maceli, AR; Dickopf, S; Papachristou, EK; D'Santos, CS; Carey, LA; Wilkinson, JE; Harrell, JC; Perou, CM; Goodarzi, H; Poulogiannis, G; Hannon, GJ (2018-02-07)
      Using a functional model of breast cancer heterogeneity, we previously showed that clonal sub-populations proficient at generating circulating tumour cells were not all equally capable of forming metastases at secondary ...
    • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 

      Khankari, NK; Shu, X-O; Wen, W; Kraft, P; Lindström, S; Peters, U; Schildkraut, J; Schumacher, F; Bofetta, P; Risch, A; Bickeböller, H; Amos, CI; Easton, D; Eeles, RA; Eeles, RA; Gruber, SB; Haiman, CA; Hunter, DJ; Chanock, SJ; Pierce, BL; Zheng, W; Colorectal Transdisciplinary Study (CORECT); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Transdisciplinary Research in Cancer of the Lung (TRICL) (2016-09-06)
      BACKGROUND:Observational studies examining associations between adult height and risk of colorectal, prostate, and lung cancers have generated mixed results. We conducted meta-analyses using data from prospective cohort ...
    • ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma. 

      Foster, H; Ruiz, EJ; Moore, C; Stamp, GWH; Nye, EL; Li, N; Pan, Y; He, Y; Downward, J; Behrens, A (2019-10)
      Tumor cells proliferate rapidly and thus are frequently subjected to replication stress and the risk of incomplete duplication of the genome. Fragile sites are replicated late, making them more vulnerable to damage when ...
    • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 

      Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11)
      BACKGROUND:Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ...
    • Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. 

      Oser, MG; Fonseca, R; Chakraborty, AA; Brough, R; Spektor, A; Jennings, RB; Flaifel, A; Novak, JS; Gulati, A; Buss, E; Younger, ST; McBrayer, SK; Cowley, GS; Bonal, DM; Nguyen, Q-D; Brulle-Soumare, L; Taylor, P; Cairo, S; Ryan, CJ; Pease, EJ; Maratea, K; Travers, J; Root, DE; Signoretti, S; Pellman, D; Ashton, S; Lord, CJ; Barry, ST; Kaelin, WG (2019-02)
      Small cell lung cancer (SCLC) accounts for 15% of lung cancers and is almost always linked to inactivating RB1 and TP53 mutations. SCLC frequently responds, albeit briefly, to chemotherapy. The canonical function of the ...
    • The changing diagnostic pathway for lung cancer patients in Shanghai, China. 

      Jiang, T; Ren, S; Li, X; Su, C; Zhou, C; O'Brien, M (2017-10)
      Accumulating evidence suggest that patients with advanced non-small-cell lung cancer (NSCLC) and specific genomic alterations including epidermal growth factor receptor and microtubule-associated protein-like 4 anaplastic ...
    • Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. 

      Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; Minchom, A; Punwani, R; Bhosle, J; Popat, S; Ratoff, J; de Bono, J; Yap, TA; O''Brien, M; Banerji, U (2016-01)
      We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small cell lung ...
    • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 

      Dimitrakopoulou, VI; Tsilidis, KK; Haycock, PC; Dimou, NL; Al-Dabhani, K; Martin, RM; Lewis, SJ; Gunter, MJ; Mondul, A; Shui, IM; Theodoratou, E; Nimptsch, K; Lindström, S; Albanes, D; Kühn, T; Key, TJ; Travis, RC; Vimaleswaran, KS; GECCO Consortium; PRACTICAL Consortium; GAME-ON Network (CORECT, DRIVE, ELLIPSE, FOCI-OCAC, TRICL-ILCCO); Kraft, P; Pierce, BL; Schildkraut, JM (2017-10-31)
      Objective To determine if circulating concentrations of vitamin D are causally associated with risk of cancer.Design Mendelian randomisation study.Setting Large genetic epidemiology networks (the Genetic Associations and ...
    • Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. 

      Jones, RL; Katz, D; Loggers, ET; Davidson, D; Rodler, ET; Pollack, SM (2017-08-29)
      Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of ...
    • The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. 

      Walton, MI; Eve, PD; Hayes, A; Henley, AT; Valenti, MR; De Haven Brandon, AK; Box, G; Boxall, KJ; Tall, M; Swales, K; Matthews, TP; McHardy, T; Lainchbury, M; Osborne, J; Hunter, JE; Perkins, ND; Aherne, GW; Reader, JC; Raynaud, FI; Eccles, SA; Collins, I; Garrett, MD (2016-01)
      CCT245737 is the first orally active, clinical development candidate CHK1 inhibitor to be described. The IC50 was 1.4 nM against CHK1 enzyme and it exhibited>1,000-fold selectivity against CHK2 and CDK1. CCT245737 potently ...
    • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. 

      Faivre-Finn, C; Snee, M; Ashcroft, L; Appel, W; Barlesi, F; Bhatnagar, A; Bezjak, A; Cardenal, F; Fournel, P; Harden, S; Le Pechoux, C; McMenemin, R; Mohammed, N; O'Brien, M; Pantarotto, J; Surmont, V; Van Meerbeeck, JP; Woll, PJ; Lorigan, P; Blackhall, F; CONVERT Study Team (2017-08)
      BACKGROUND:Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard ...
    • Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. 

      Yap, TA; Macklin-Doherty, A; Popat, S (2017-01)
      The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and ...
    • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 

      Scarbrough, PM; Weber, RP; Iversen, ES; Brhane, Y; Amos, CI; Kraft, P; Hung, RJ; Sellers, TA; Witte, JS; Pharoah, P; Henderson, BE; Gruber, SB; Hunter, DJ; Garber, JE; Joshi, AD; McDonnell, K; Easton, DF; Eeles, R; Kote-Jarai, Z; Muir, K; Doherty, JA; Schildkraut, JM (2016-01)
      DNA damage is an established mediator of carcinogenesis, although genome-wide association studies (GWAS) have identified few significant loci. This cross-cancer site, pooled analysis was performed to increase the power to ...
    • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 

      Fehringer, G; Kraft, P; Pharoah, PD; Eeles, RA; Chatterjee, N; Schumacher, FR; Schildkraut, JM; Lindström, S; Brennan, P; Bickeböller, H; Houlston, RS; Landi, MT; Caporaso, N; Risch, A; Amin Al Olama, A; Berndt, SI; Giovannucci, EL; Grönberg, H; Kote-Jarai, Z; Ma, J; Muir, K; Stampfer, MJ; Stevens, VL; Wiklund, F; Willett, WC; Goode, EL; Permuth, JB; Risch, HA; Reid, BM; Bezieau, S; Brenner, H; Chan, AT; Chang-Claude, J; Hudson, TJ; Kocarnik, JK; Newcomb, PA; Schoen, RE; Slattery, ML; White, E; Adank, MA; Ahsan, H; Aittomäki, K; Baglietto, L; Blomquist, C; Canzian, F; Czene, K; Dos-Santos-Silva, I; Eliassen, AH; Figueroa, JD; Flesch-Janys, D; Fletcher, O; Garcia-Closas, M; Gaudet, MM; Johnson, N; Hall, P; Hazra, A; Hein, R; Hofman, A; Hopper, JL; Irwanto, A; Johansson, M; Kaaks, R; Kibriya, MG; Lichtner, P; Liu, J; Lund, E; Makalic, E; Meindl, A; Müller-Myhsok, B; Muranen, TA; Nevanlinna, H; Peeters, PH; Peto, J; Prentice, RL; Rahman, N; Sanchez, MJ; Schmidt, DF; Schmutzler, RK; Southey, MC; Tamimi, R; Travis, RC; Turnbull, C; Uitterlinden, AG; Wang, Z; Whittemore, AS; Yang, XR; Zheng, W; Buchanan, DD; Casey, G; Conti, DV; Edlund, CK; Gallinger, S; Haile, RW; Jenkins, M; Le Marchand, L; Li, L; Lindor, NM; Schmit, SL; Thibodeau, SN; Woods, MO; Rafnar, T; Gudmundsson, J; Stacey, SN; Stefansson, K; Sulem, P; Chen, YA; Tyrer, JP; Christiani, DC; Wei, Y; Shen, H; Hu, Z; Shu, X-O; Shiraishi, K; Takahashi, A; Bossé, Y; Obeidat, M; Nickle, D; Timens, W; Freedman, ML; Li, Q; Seminara, D; Chanock, SJ; Gong, J; Peters, U; Gruber, SB; Amos, CI; Sellers, TA; Easton, DF; Hunter, DJ; Haiman, CA; Henderson, BE; Hung, RJ; Ovarian Cancer Association Consortium (OCAC); PRACTICAL Consortium; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Colorectal Transdisciplinary (CORECT) Study; African American Breast Cancer Consortium (AABC) and African Ancestry Prostate Cancer Consortium (AAPC) (2016-09)
      Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, ...
    • Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? 

      Reck, M; Kerr, KM; Grohé, C; Manegold, C; Pavlakis, N; Paz-Ares, L; Huber, RM; Popat, S; Thatcher, N; Park, K; Hilberg, F; Barrueco, J; Kaiser, R (2019-04)
      A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based ...
    • Development of molecularly targeted agents and immunotherapies in small cell lung cancer. 

      Sharp, A; Bhosle, J; Abdelraouf, F; Popat, S; O'Brien, M; Yap, TA (2016-06)
      Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination ...
    • Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. 

      Taylor, SA; Mallett, S; Ball, S; Beare, S; Bhatnagar, G; Bhowmik, A; Boavida, P; Bridgewater, J; Clarke, CS; Duggan, M; Ellis, S; Glynne-Jones, R; Goh, V; Groves, AM; Hameeduddin, A; Janes, SM; Johnston, EW; Koh, D-M; Lock, S; Miles, A; Morris, S; Morton, A; Navani, N; Oliver, A; O'Shaughnessy, T; Padhani, AR; Prezzi, D; Punwani, S; Quinn, L; Rafiee, H; Reczko, K; Rockall, AG; Russell, P; Sidhu, HS; Strickland, N; Tarver, K; Teague, J; Halligan, S; Streamline investigators (2019-06)
      BACKGROUND:Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, ...